Fludarabine, cyclophosphamide and rituximab (FCR) is the standard chemotherapy regimen used to treat chronic lymphocytic leukaemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, provides an overview of the Phase III CLL10 study (NCT00769522), which compared the efficacy and tolerance of FCR vs. bendamustine in combination with rituximab. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Bendamustine plus rituximab vs. standard therapy for advanced CLL
